AVA6000 is basically doing to SGC what Daraxonrasib is doing to pancreatic. They are hailing the increased overall survival rate, not complete remission. Imagine what AVA6103 would do regarding pancreatic and what the public response could be to that. #avct
@Anthony__VR Yes, but Daraxonrasib being phase 2 I believe and for a larger disease setting (SGC very small compared to pancreatic)... But imagine if AVA6103 does to pancreatic compared to what it does in mice? Then it humbles daraxonrasib...
Dronken door het rood rijden of een rechter die iemand veroordeelt vanwege het weergeven van feiten... Niet vergelijkbaar. Zolang het maar in links zijn kraam past worden er geen kritische vragen gesteld. You know it, we know it... you know it we know it... but you obviously couldn't care less. :-)
@TonyRob70579912@MylesMcNulty@sandyradders@Josh44282819@glr_1990@BigBiteNow Agree. On the other hand, you have a huge amount of "ride or die" shareholders like me, who have ridden the rollercoaster for more than 5 years. I ride or die, and I'll not be the only one. #avct This company seems to hold the holy grail of the worldwide oncology industry
@MylesMcNulty@sandyradders@Josh44282819@glr_1990@BigBiteNow "band together" indeed... It would almost make sense to create some kind of a critical shareholder-group that has one spokesperson that align on their take over targets #avct Bundle the voting power. I'd be happy to lend my voting.